Application of rutin in preparation of medicine or health care product for promoting sleep

Abstract

The invention discloses application of rutin in preparation of a medicine or a health care product for promoting sleep, and belongs to the technical field of biological medicine. Rutin can increase non-fast eye movement sleep time, has a potential insomnia treatment effect, and has a good application prospect in preparation of sedative-hypnotic drugs and health care products. The rutin medicines and health-care products prepared by the invention comprise medicine excipients or carriers allowed by preparations, and can be prepared into dosage forms of intestinal or non-intestinal combined medicines according to known methods in the field of preparations, and the preparation forms mainly comprise granules, tablets, liquid preparations, sustained-release preparations, electuary, capsules, capsules or injections.

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to application of rutin in preparing medicines or health products for promoting sleep. Background Art

[0002] Sleep plays a vital role in human physiological and mental health. However, due to factors such as increased life pressure, intensified social competition, nightlife and bad living habits, many people face insomnia and sleep disorders. One-third of the world's people have sleep problems, and 5% of them need to rely on drugs to maintain sleep. Long-term insomnia can lead to memory impairment, depression, anxiety, low immune function, aggravate other diseases or induce the onset of existing diseases (such as cardiovascular and cerebrovascular accidents). Sleep disorders have become a serious social and medical problem.

[0003] Benzodiazepines commonly used in clinical practice The sleep EEG wave patterns induced by sleeping pills are significantly different from physiological sleep waves, indicating that sleeping pills may change the normal sleep pattern of the human body, and the brain does not actually get enough rest. Patients often experience drowsiness, dizziness, fatigue, etc. the next morning after taking the medicine. Long-term use can also lead to drug resistance and dependence. Therefore, the development of hypnotic drugs that can induce high efficiency and low dependence similar to physiological sleep has great social and economic significance. Summary of the invention

[0004] The purpose of the present invention is to provide an application of rutin in the preparation of a medicine or health product for promoting sleep, so as to solve the problems existing in the above-mentioned prior art.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] One of the technical solutions of the present invention is the use of rutin in the preparation of medicines or health products for promoting sleep.

[0007] The second technical solution of the present invention is the use of rutin in the preparation of medicines or health products for promoting non-rapid eye movement (NREM) sleep.

[0008] The third technical solution of the present invention is a sleep medicine or health product, comprising rutin.

[0009] Based on the above technical solution, the present invention has the following technical effects:

[0010] The present invention provides a new use of rutin for sedation and hypnosis. Rutin and its derivatives have wide sources, low toxicity, low addiction and low dependence. Therefore, the present invention provides a new choice and a strong basis for the development of rutin and its derivatives in natural sedation and hypnosis drugs, and has broad development space and good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0012] Figure 1 This is the time course curve of rutin increasing NREM sleep. The open circles and solid circles represent the amount of NREM sleep per 30 min in the vehicle group and the drug group, respectively. The values ​​are mean ± standard error, n = 5. Compared with the vehicle group, *P < 0.05, **P < 0.01, and the statistical method used was two-way ANOVA. .

[0013] Figure 2 Rutin increases NREM sleep after medication. The hollow and solid bars represent the amount of NREM sleep in the vehicle group and 3 hours after medication, respectively. Values ​​are mean ± standard error, n = 5. Compared with the vehicle group, *P < 0.05, the statistical method used was paired t test. DETAILED DESCRIPTION

[0014] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0015] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0016] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0017] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0018] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0019] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or have been disclosed.

[0020] The embodiment of the present invention provides the use of rutin in preparing a medicine or health product for promoting sleep.

[0021] The embodiment of the present invention also provides the use of rutin in preparing medicines or health products for promoting NREM sleep.

[0022] In some specific embodiments, the structural formula of rutin is as follows:

[0023]

[0024] In some specific embodiments, the rutin is a natural flavonoid compound, a flavonol glycoside widely found in plants, and has a light yellow or light green crystalline powder appearance, CAS number: 153-18-4; molecular formula: C 27 H 30 O 16 ; Molecular weight: 610.52.

[0025] The embodiment of the present invention further provides a sleep medicine or health product, comprising rutin.

[0026] In some specific embodiments, the dosage form is a liquid preparation, granules, powder, tablet or capsule.

[0027] In some specific embodiments, the administration is oral administration, transdermal administration or injection administration.

[0028] Rutin, also known as rutin and vitamin P, is called Rutin in English. Modern medicine has proven that it has antioxidant, anti-inflammatory, anti-viral, anti-apoptosis, and anti-tumor effects.

[0029] Rutin is widely distributed in plants that make up a large part of the human diet, such as Arabica coffee, Schisandra chinensis, buckwheat, kidney beans and Sophora japonica buds. Modern medical evidence shows that flavonoids such as rutin have antioxidant, anti-inflammatory, antiviral, anti-apoptotic and anti-tumor effects.

[0030] The rutin used in the present invention is extracted from Sophora japonica buds according to the prior art. The present invention finds that after administration of rutin, the non-rapid eye movement sleep time can be significantly increased, and the body is in a sleeping state.

[0031] Example 1

[0032] Effects of rutin on sleep in mice:

[0033] 1 Experimental animals

[0034] Male C57BL / 6J mice, SPF grade, 10-13 weeks old, 23-25 ​​g, were purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences. Rearing conditions: room temperature (22±1)℃, humidity (50±10)%, 12-h light-dark rhythmic cycle, free access to water and food.

[0035] 2 Experimental methods

[0036] Electrodes for recording EEG and EMG were implanted on the surface of the mouse skull. The experiment was conducted after the animals recovered for 10 days, and the electrode connection wires were connected 3 days before the recording. The administration groups were: vehicle (containing 10% DMSO, 90% Saline) control group, rutin (100 mg / kg) experimental group, 5 mice in each group, and the administration method was intraperitoneal injection.

[0037] The EEG and EMG signals of mice were amplified, filtered, and converted into digital signals by the sleep bioanalysis system, and then recorded using SleepSign software (Kissei Comtec, Nagano, Japan). The recording started at 19:00 and lasted for 48 hours. The solvent was given at 21:00 on the first day as a self-control, and the drug rutin was given to the animals at 21:00 on the second day. After the EEG / EMG recording was completed, SleepSign analysis software was used to automatically scan according to the uniformly set standards with 10 seconds as the analysis unit to distinguish wakefulness (wake, W), NREM sleep and rapid eye movement (rapid eye movement, REM) sleep. After the automatic scanning was completed, manual inspection was performed and corrections were made if necessary.

[0038] 3 Experimental results

[0039] In order to detect the effect of rutin on sleep, 100 mg / kg of rutin was intraperitoneally injected. Compared with the vehicle control group, rutin increased NREM sleep starting from the second hour after administration and the effect lasted for 1.5 hours ( Figure 1 The cumulative amount of NREM sleep within 3 hours after administration was 2 times higher in 100 mg / kg rutin compared to the vehicle control group ( Figure 2 ). But it had no effect on REM sleep. The above results suggest that rutin can increase NREM sleep.

[0040] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. Application of rutin in the preparation of drugs or health products that promote sleep.

2. Application of rutin in the preparation of medicines or health products for promoting non-rapid eye movement sleep.

3. The use according to claim 1 or 2, characterized in that: The structural formula of the rutin is as follows:

4. A sleep medicine or health product, characterized in that: Includes rutin.

5. The medicine or health product according to claim 4, characterized in that: The dosage form is liquid preparation, granules, powder, tablet or capsule.

6. The medicine or health product according to claim 4, characterized in that: The administration method is oral administration, transdermal administration or injection.

Images